Picture Kentro Design Is Key to Your Success Berlin 650x100px

Product › Details

Quinvaxem™

	Next higher product group	vaccine, combination_o
	Status	2006-10-01 sales start
	Organisation	Crucell N.V. (Euronext: CRXL, Nasdaq: CRXL)
	Group	Johnson & Johnson (JnJ) (Group)

Record changed: 2023-07-10

Picture Berlin Partner Top News Healthtech Company Mika 650x200px

More documents for vaccine

[1] CureVac N.V.. (4/24/24). "Press Release: CureVac Appoints Thaminda Ramanayake as New Chief Business Officer". Tübingen & Boston, MA....
[2] CureVac N.V.. (4/16/24). "Press Release: CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines". Tübingen & Houston, TX....
[3] Naobios. (4/15/24). "Press Release: Naobios and Sumagen Sign Exclusive Partnership to Develop HIV Vaccine". Nantes....
[4] BioNTech SE. (3/20/24). "Press Release: BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer". Mainz....
[5] ReiThera S.r.l.. (1/22/24). "Press Release: ReiThera Srl, the Ragon Institute and IAVI Announce Collaboration to Advance Highly Networked T Cell HIV Vaccine Candidate Towards Phase I Clinical Evaluation". Rome & Cambridge, MA....
[6] CureVac N.V.. (1/17/24). "Press Release: CureVac CEO Alexander Zehnder Acquires Common Shares of Company Stock". Tübingen & Boston, MA....
[7] CureVac N.V.. (1/5/24). "Press Release: CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform". Tübingen & Boston, MA....
[8] Hookipa Pharma Inc.. (12/21/23). "Press Release: Hookipa Pharma Announces $21.25 Million Equity Investment from Gilead Sciences". New York, NY & Vienna....
[9] LimmaTech Biologics AG. (12/19/23). "Press Release: LimmaTech Biologics Expands Vaccine Pipeline by Licensing AbVacc’s Innovative Vaccine Candidate Against Staphylococcus aureus". Schlieren & Rockville, MD....
[10] CureVac N.V.. (12/19/23). "Press Release: CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE". Tübingen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]